FDA Approval of Alectinib for ALK-Positive Metastatic Lung Cancer Treatment – 2015
Reading tools
Alectinib (Alecensa®), which received FDA approval on 11 December 2015;
In patients unable to tolerate the drug called Crizotinib and with advanced ALK (anaplastic lymphoma kinase)-positive disease spread to distant tissues (metastatic), with non-small cell lung cancer , it is used. Alectinib prevents cancer cell viability by stopping the functioning of the protein-structured genes/molecules called ALK and RET that confer susceptibility to cancer. Fatigue, muscle pain, constipation and edema (swelling) are its most common side effects.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.